the cost is covered by public payers, a sizable proportion (33–37%) of the hospitalizations for bipolar disorder, depression, and substance use disorders are covered by private payers.

Mental Health—Patient-Reported Outcomes

PMH46

Predictors of Medication Adherence Among Schizophrenia Patients Treated with Conventional and Atypical Antipsychotics in a Large State Medicaid Program

Lee SP1, Lang K1, Jackel J2, Crivera C1, Dirani RG1, Menzin J1

1Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 2Boston Health Economics, Inc, Waltham, MA, USA, 3Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA

Objective: This study evaluated antipsychotic use in Medicaid beneficiaries with a schizophrenia disorder and identified factors associated with poor adherence. Methods: This study involved a retrospective cohort analysis of non-dual Florida Medicaid recipients who had a medical claim indicating a schizophrenia disorder (ICD-9-CM 295.XX) and received an antipsychotic (APS) medication between July 1, 2004 and June 30, 2005. Patients were followed for one year after the first APS prescription. Adherence was measured using the Medication Possession Ratio (MPR; defined as unduplicated ambulatory treatment days divided by the number of ambulatory days in the period), medication persistence (days between the first and last antipsychotic in the follow-up period), and number of untreated days. Logistic regression models were used to identify predictors of poor adherence (MPR < 0.80). Results: A total of 8828 patients met inclusion criteria. Mean (±SD) age was 42.3 (±13.7) years, 49% were female, and 36.8% were white. Approximately 18% and 39% had pre-existing diagnoses of substance abuse or other psychiatric conditions, respectively. Mean (±SD) MPR was 0.72 (±0.3). The mean number of untreated days was 47.4 (±60.8), and mean persistence was 311.9 (±120.5) days. Approximately 57% of patients had MPR values between 0.8 and 1. Logistic regression indicated that younger patients (<18 years), females, nonwhites, those with a substance abuse diagnosis or who received antidepressants, and those newly starting APS therapy were significantly more likely to be poorly adherent, while those treated with atypical or injectable antipsychotics (vs. conventional orals) were less likely to be poorly adherent. Conclusion: Several patient characteristics are predictive of poor adherence to APS therapy. Study findings may be informative to health plan administrators interested in identifying patients at risk for medication non-adherence.

PMH48

Better Persistence on Treatment with Escitalopram Compared with Citalopram

Freshesky L1, Despiégel N2, Maman K2, François C2, Saragoussi D2

1California Clinical Trials, Glendale, CA, USA, 2Lundbeck SAS, Paris, France

Objective: Guidelines recommend use of antidepressants for a minimum of six months in major depressive disorder in order to decrease the risk of relapse. Persistence on treatment depends both on efficacy and tolerability. In clinical trials, escitalopram has shown a better efficacy and equivalent tolerability compared with citalopram. This work compares persistence on treatment at six months and associated economic consequences, for treatment with escitalopram vs. citalopram. Methods: Using US denominator-based claims database PharMetrics (includes data from 86 managed care health plans covering 45 million patients), we included adult patients diagnosed with depression who started escitalopram or citalopram between January 1, 2003 and December 31, 2004. Six-months persistence was defined as the percentage of patients still on treatment at 6 months. We compared persistence over time using Cox model, and health care costs at 6 months using log-linear regression. Propensity scoring was used to account for channelling by indication. Results: A total of 13,227 patients started escitalopram; 3,624 patients started citalopram. Persistence at 6 months was 20.4% with escitalopram vs. 16.2% with citalopram (p < 0.001). Escitalopram-treated patients were more likely to be persistent over 6-months than citalopram-treated patients adjusted for their baseline characteristics (HR = 0.896; 95% CI: [0.859–0.934]). More were observed on citalopram than on escitalopram (7.8 vs. 6.2, p < 0.001). Total health care costs over 6-months (including treatment cost) were non-significantly lower for escitalopram-treated patients than for citalopram-treated patients (-USD232 per patient; p = 0.2). Persisters at 6 months incurred less total health care costs than non-persisters (-USD280 over the 6 months). Conclusion: Persistence at 6 months is higher on escitalopram than on citalopram, in consistency with its better...
efficacy profile. Persistence at 6 months is recommended to maximize chances of sustained remission and to avoid relapse; interestingly these results show that persistence is also associated with decreased health care costs. Efforts should be made to promote persistence on antidepressant treatment.

**PMH49**

**EARLY DISCONTINUATION ON TREATMENT AND ITS CONSEQUENCES IN PATIENTS TREATED WITH VENLAFAXINE OR ESCITALOPRAM**

Ereshefsky L, Courmau S, Hansen K, Milea D, Verpillat P

1California Clinical Trials, Glendale, CA, USA, 2Lundbeck SAS, Paris, France

**OBJECTIVE:** Two-month head-to-head clinical trials of escitalopram and venlafaxine demonstrated similar efficacy and better tolerability for escitalopram. As routine practice may differ from controlled trial, policy makers wonder how clinical trial findings translate into real life outcomes in community practice. This work compares early treatment discontinuation (ETD) rates at 1 and 2 months and its economic consequences at 6 months, for patients with depression treated with venlafaxine and escitalopram.

**METHODS:** Using US denominator-based claims database PharMetrics (includes data from 86 managed care health plans covering 45 million patients), we included adult patients diagnosed with depression who started venlafaxine or escitalopram between January 1, and December 31, 2004. We compared ETD at 1 and 2 months using Cox proportional hazard models and health care costs at 6 months, using log-linear regression. Propensity scoring was used to account for channeling by indication.

**RESULTS:** A total of 13,227 patients started escitalopram; 5,922 patients started venlafaxine. ETD at 2 months was 47% for venlafaxine, 45% for escitalopram. At 1 month, venlafaxine patients had a 50% greater risk of ETD than escitalopram patients (Hazard Ratio = 0.493 [95% CI 0.432-0.564]); this difference decreased at 2 months (Hazard Ratio = 0.955 [95% CI 0.912-0.999]). Six-month health care costs were higher with venlafaxine (+USD626, p < 0.01). Patients continuing treatment at 2 months had 36% chance of still being on treatment at 6 months. Patients (all treatments) with ETD at 2 months incurred more costs over 6 months (+USD350) compared to patients continuing treatments.**CONCLUSION:** Early treatment discontinuation rate was higher with venlafaxine than escitalopram, possibly due to intolerance to venlafaxine. Absence of ETD was associated with long term persistence and lower total treatment costs.

**PMH50**

**A NEW MEASURE OF ADHERENCE—THE DAILY POSSESSION RATIO (DPR): COMPARISONS WITH THE MEDICATION POSSESSION RATIO (MPR) IN THE PRESENCE OF MEDICATION SWITCHING AND THERAPEUTIC DUPLICATION**

Martin BC, Wiley-Exley E, Richards S, Domino ME, Carey T

1University of Arkansas for Medical Sciences, Little Rock, AR, USA, 2University of North Carolina, Chapel Hill, NC, USA

**OBJECTIVE:** The objectives of this study are to describe and define a new adherence measure, the Daily Possession Ratio (DPR), and to contrast that measure with two variants of the Medication Possession Ratio (MPR, truncated MPR).**METHODS:** This study was a retrospective analysis of the North Carolina Medicaid administrative claims data from July 1999 to June 2000. Data for non-HMO, non-hospitalized, non-pregnant schizophrenia patients (ICD-9-CM = 295.**) with at least one antipsychotic were aggregated to the person-quarter level. The daily possession ratio was defined as the number of days one or more antipsychotics was available divided by the total days in the quarter. Adherence rates were also estimated for subjects that switched medications or had therapeutic duplication in the quarter.**RESULTS:** The final sample consisted of 25,200 person-quarters from 7,069 individuals. For person quarters with single antipsychotic use, adherence to antipsychotics as a class was: DPR = 0.607; truncated MPR = 0.640; MPR = 0.695 (p < 0.0001). For person quarters with therapeutic duplication, the following adherence measures were observed: DPR = 0.669; truncated MPR = 0.774; MPR = 1.238 (p < 0.0001).**CONCLUSION:** The DPR provides a more conservative estimate of adherence than the MPR across all types of users, however the differences between the two methods are more substantial for persons switching therapy and prescribed therapeutic duplica-